News Articles for Emyria

Bluetooth pill dispensers, autonomous ship navigation, stylish safety glasses, and MDMA and Psilocybin-assisted therapy have been recognised at this year's Innovator of the Year awards night.

The private insurer is the first major brand to fund a psychotherapy-led treatment-resistant depression program in Australia.

Emyria wants to roll out its psychedelic-assisted mental health treatments nation-wide under recent agreements with Medibank and Avive Health.

Our board moves wrap includes Luke Meter, YaXi Zhan, Greg Hutchinson, Henry Heng, Colin Moran, Richard Mei, Brett Crowley, and Aldo Miccio.

Our board moves wrap includes Alistair Vickery, Stewart Washer, Karen Smith, Tracey Horton, Peter Gundy, Clint Moxham, Carla Healy, Damon Fieldgate, Paul Farrell, and Andrew Brown.

Our board moves wrap includes Jeremy Robinson, Matt Freedman, Michelle Roth, Bruce McFadzean, Mohit Kaushal, Matt Callahan, Simon Linge, and Bruce Munro.

Health tech has taken a front seat in recent months thanks to the combined funding from government and private sectors.

Our board moves wrap includes Chris Radin, Sheila Khama, Stirling Ross, Gerry Kaczmarek, Tony Kiernan, Derek Humphry, Dale Richards, Nerida Schmidt, Patricia Farr, Simon Robertson, Susan Park, Peter Webse, ChongTao Xu, Andrew Taplin, Carol Marinkovich, Rowan Harland, Arron Canicais, David Lim, Andrew Woskett, Benjamin Donovan, and Shaun Menezes.

The commercial side of life sciences may have reached a critical mass in WA.

A $250 million venture capital initiative launched by the Forrest family seeks to leverage the millions of dollars of health-related R&D funding by governments and bridge the commercialisation 'valley of death' faced by many startups.

Graham Upson is sharing his knowledge with a company seeking to grow mushrooms for mental health.

Andrew Forrest-backed Emyria is slated to start human clinical trials within weeks for a cannabinoid drug to treat psychological distress.

Our board moves wrap includes Neville Bassett, Neil Marston, Michele Anderson, Karen Smith, Debra Singh, Toni Thornton, David Foster, Mark Johnson, Gerard McMahon, Neale Edwards, and Matt Briggs.

Shares in Perth-based medicinal cannabis aspirant Emyria were up as much as 21 per cent after the business revealed a $5 million backing from Andrew Forrest's investment business, Tattarang.

Fifty Perth-based companies and organisations - including education institutions, numerous local startups and not for profits and mining giants have been announced as finalists for the INCITE Award

Our board moves wrap includes Stephen McIntosh, Manuel Ramos, Karen Smith, Tom Wilcox, and Oonagh Malone.

A post-pandemic bounce back in initial public offerings could indicate confidence among WA investors.

The strong growth of the medicinal cannabis industry will need to be supported by research for the sector to take the next step.

Perth's largest drug testing company plans to nearly double capacity as WA attracts attention from global pharmaceutical companies.

COVID-19 has taken a wrecking ball through the IPO market, cutting raisings by 80 per cent, although those that proceeded outperformed other equities.

Emerald Clinics and Little Green Pharma have both completed their initial public offerings ahead of stock market listings this month, with Emerald getting ready for its ASX debut tomorrow.

The state government has appointed an industry reference group to develop a growth plan for WA's health and medical life sciences sector to be chaired by Peter Klinken.

Perth companies Emerald Clinics and Little Green Pharma are seeking to raise up to $18 million ahead of stock market listings as they pursue very different strategies in the medicinal cannabis market.

With mainstream acceptance for cannabinoid medicines growing, Emerald Clinics has found value in building clinical evidence of its use.

Medicinal cannabis research company Emerald Clinics has boosted its management team with the appointment of Michael Winlo as chief executive, ahead of an expected IPO later this year.